- Market Size (2026)
- USD 18.8 Bn
- Forecast (2036)
- USD 39.2 Bn
- CAGR (2026 to 2036)
- 7.6%
Fecal Pancreatic Elastase Testing Market Size, Market Forecast and Outlook By FMI
The fecal pancreatic elastase testing market was valued at USD 17.5 billion in 2025. The market is set to reach USD 18.8 billion by 2026-end and grow at a CAGR of 7.6% between 2026-2036 to reach USD 39.2 billion by 2036. Fecal Pancreatic Elastase ELISA Kits will dominate with a 61.0% share, while Stool Samples will lead with a 88.0% share.
Key Takeaways, Market Size, and Forecast
- 2026 Market Size: USD 18.8 billion
- 2036 Market Size: USD 39.2 billion
- Compound Annual Growth Rate (CAGR): 7.6% from 2026 to 2036
- Absolute $ Opportunity: USD 20.4 billion between 2026 and 2036
- Leading Product Segment: Fecal Pancreatic Elastase ELISA Kits
- Fecal Pancreatic Elastase ELISA Kits Share in 2026: 61%
- Fastest-growing Country: USA
- USA CAGR: 7.7% through 2036
| Parameter | Details |
|---|---|
| Market Size in 2026 (Value) | USD 18.8 billion |
| Market Forecast in 2036 (Value) | USD 39.2 billion |
| CAGR (2026 to 2036) | 7.6% |
| Years Considered | 2021 to 2036 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2036 |
| Units Considered | Value (USD Billion) |
| Leading Sub-Region | USA |
Summary of the Fecal Pancreatic Elastase Testing Market
- Demand and Growth Drivers
- Demand for fecal pancreatic elastase testing is expanding as gastroenterologists and endocrinologists adopt the FPE-1 assay as the standard non-invasive test for diagnosing exocrine pancreatic insufficiency in patients with chronic pancreatitis, cystic fibrosis, and diabetes-related pancreatic dysfunction.
- Fecal pancreatic elastase ELISA kits account for 61.0% of the product segment in 2026, reflecting their established role as the clinical reference standard for quantitative pancreatic exocrine function assessment.
- Expanding clinical awareness of EPI as an underdiagnosed condition is broadening test utilization beyond specialist gastroenterology into primary care and endocrinology settings.
- Product and Segment View
- Fecal pancreatic elastase ELISA kits hold 61.0% of the product segment in 2026, providing quantitative measurement of elastase concentration in stool samples for EPI diagnosis.
- Healthcare providers hold the largest end use share, with hospital gastroenterology departments and specialty clinics driving procurement of FPE-1 testing products and services.
- EPI diagnosis is the primary application, with chronic pancreatitis, cystic fibrosis, and diabetes-related pancreatic dysfunction as the core clinical indications for testing.
- Geography and Competitive Outlook
- The USA leads at 7.7% CAGR, supported by clinical guideline adoption, growing EPI awareness among gastroenterologists and endocrinologists, and expanding health insurance coverage for pancreatic function testing.
- Japan at 7.6% reflects advanced clinical diagnostic practices, aging population pancreatic disease prevalence, and established hospital laboratory infrastructure for specialized immunoassay testing.
- ScheBo Biotech AG holds the leading competitive position as the originator of the pancreatic elastase-1 stool test with the most extensive clinical validation dataset globally.
- Analyst Opinion
- Nandini Roy Choudhury, Principal Consultant at FMI says, 'Diagnostic companies that can expand clinical awareness of EPI as an underdiagnosed condition while delivering validated, easy-to-use testing solutions for gastroenterology and primary care settings are positioned to capture the growing adoption of pancreatic function testing through 2036.'
- The fecal pancreatic elastase testing market is evolving from specialist diagnostic use to broader clinical adoption as EPI recognition improves among primary care physicians and endocrinologists managing patients with diabetes and chronic GI symptoms.
- Adoption of point-of-care rapid FPE-1 test formats is increasing due to the need for clinic-based screening that enables same-visit diagnosis and treatment initiation for symptomatic patients.
- Demand is further supported by the growing prevalence of chronic pancreatitis and diabetes-related pancreatic dysfunction in aging populations across developed markets.
Fecal Pancreatic Elastase Testing Market Definition
The fecal pancreatic elastase testing market encompasses diagnostic assays, test kits, and testing services that measure pancreatic elastase-1 concentration in stool samples as a biomarker for exocrine pancreatic insufficiency. Products include ELISA kits, rapid immunochromatographic tests, and automated laboratory testing platforms used for EPI diagnosis, treatment monitoring, and pancreatic function assessment.
Fecal Pancreatic Elastase Testing Market Inclusions
Market scope covers all commercially traded fecal pancreatic elastase testing products categorized by product, sample, application, technology, end use, distribution channel. Revenue is tracked from 2026 to 2036.
Fecal Pancreatic Elastase Testing Market Exclusions
The scope does not include serum pancreatic enzyme tests (amylase, lipase), secretin stimulation tests, or imaging-based pancreatic function assessments such as MRI or CT.
Fecal Pancreatic Elastase Testing Market Research Methodology
- Primary Research: FMI analysts conducted interviews with diagnostic manufacturers, gastroenterology specialists, clinical laboratory managers, and pancreatic disease research centers.
- Desk Research: Combined data from gastroenterology practice guideline organizations, diagnostic testing regulatory databases, and pancreatic disease epidemiology studies.
- Market Sizing and Forecasting: Bottom-up aggregation from test kit sales, laboratory service revenues, and clinical adoption rate projections with regional EPI prevalence estimates.
- Data Validation: Cross-checked quarterly against diagnostic product shipment data, laboratory test volume reports, and clinical practice guideline adoption tracking.
Why is the Fecal Pancreatic Elastase Testing Market Growing?
- Growing clinical recognition of EPI as an underdiagnosed condition is the primary demand driver, expanding test utilization as gastroenterologists, endocrinologists, and primary care physicians screen symptomatic patients with chronic pancreatitis, diabetes, and unexplained GI symptoms.
- The USA leads at 7.7% CAGR, supported by AGA guideline endorsement, clinical education programs on EPI recognition, and expanding insurance coverage for pancreatic function testing.
The fecal pancreatic elastase testing market is expanding at 7.6% CAGR from 2026 to 2036, reflecting growing clinical adoption of the FPE-1 assay as the standard non-invasive diagnostic test for exocrine pancreatic insufficiency. The market is projected to create an absolute opportunity of USD 20.3 billion between 2026 and 2036.
ELISA-based FPE-1 kits dominate at 61.0%, providing quantitative elastase measurement that enables grading of EPI severity. Elastase levels below 200 micrograms per gram indicate mild to moderate EPI, while levels below 100 micrograms per gram indicate severe insufficiency. Rapid immunochromatographic tests are gaining traction for clinic-based screening.
Clinical indications span chronic pancreatitis, cystic fibrosis, diabetes-associated pancreatic dysfunction, post-surgical pancreatic insufficiency, and elderly patients with unexplained malabsorption. The recognition of EPI as an underdiagnosed condition with significant clinical impact on nutritional status and quality of life is broadening the clinical population considered for testing.
Market Segmentation Analysis
- Fecal pancreatic elastase ELISA kits hold 61.0% of the product segment, providing quantitative pancreatic function assessment for laboratory-based diagnosis.
- EPI diagnosis is the primary application, with chronic pancreatitis, cystic fibrosis, and diabetes-related dysfunction as core clinical indications.
- Hospital gastroenterology departments and specialty clinics represent the primary end user categories for FPE-1 testing procurement.
The fecal pancreatic elastase testing market segments by product type, sample type, application, technology, end use, and distribution channel. ELISA kits lead the product category, while stool sample testing is standard. EPI diagnosis and monitoring is the primary application. Healthcare providers are the dominant end users.
Insights into the Fecal Pancreatic Elastase ELISA Kits Segment
ELISA kits hold 61.0% of the product segment in 2026. The FPE-1 ELISA measures human pancreatic elastase-1 concentration in stool samples, providing a stable and specific biomarker unaffected by enzyme replacement therapy. This enables accurate diagnosis even in patients already receiving pancreatic enzyme supplementation.
Automated immunoassay integration is expanding as hospital laboratories incorporate FPE-1 testing into multi-analyte diagnostic platforms. Point-of-care rapid tests using lateral flow technology provide semi-quantitative screening results for clinic-based use where same-visit diagnosis supports immediate treatment initiation.
Insights into the EPI Diagnosis Application Segment
EPI diagnosis is the largest application, where FPE-1 testing replaces invasive and cumbersome pancreatic function assessments. Chronic pancreatitis is the most common clinical indication, followed by cystic fibrosis screening, diabetes-associated pancreatic dysfunction assessment, and post-surgical pancreatic insufficiency evaluation.
Treatment monitoring represents a growing application where serial FPE-1 measurements assess pancreatic enzyme replacement therapy adequacy. The test serves as a baseline and follow-up tool that tracks pancreatic exocrine function over time in patients with progressive pancreatic disease.
Fecal Pancreatic Elastase Testing Market Drivers, Restraints, and Opportunities
- Growing clinical recognition of EPI as an underdiagnosed condition is expanding test utilization across gastroenterology, endocrinology, and primary care settings.
- Limited clinical awareness of EPI among primary care physicians constrains testing volumes in settings where many symptomatic patients are initially evaluated.
- Diabetes-associated pancreatic dysfunction screening represents a large untapped testing opportunity as EPI prevalence in diabetic populations becomes better characterized.
The fecal pancreatic elastase testing market is shaped by EPI diagnostic awareness, clinical guideline adoption, and the growing recognition of pancreatic exocrine dysfunction in diabetes and aging populations. Growth is constrained by limited primary care awareness, while opportunities exist in diabetic screening and treatment monitoring.
EPI Diagnostic Awareness Growth
Demand is shaped by improving clinical recognition of EPI as a common but underdiagnosed condition affecting patients with chronic pancreatitis, diabetes, and elderly malabsorption. Clinical education programs and guideline endorsement are expanding the population of physicians who consider FPE-1 testing as part of standard GI symptom evaluation.
Primary Care Awareness Limitations
Growth is constrained by limited awareness of EPI and FPE-1 testing among primary care physicians, where many patients with undiagnosed EPI present initially with non-specific GI symptoms. Clinical education and point-of-care test availability are gradually addressing this awareness gap, but adoption in primary care remains below specialist gastroenterology utilization.
Diabetes-Associated EPI Screening
Adoption is increasing as clinical evidence establishes elevated EPI prevalence in type 1 and type 2 diabetes populations. Screening diabetic patients with unexplained GI symptoms for pancreatic exocrine insufficiency represents a large untapped testing opportunity that could significantly expand the addressable market for FPE-1 testing.
Analysis of Fecal Pancreatic Elastase Testing Market By Key Countries
.webp "Top Country Growth Comparison Fecal Pancreatic Elastase Testing Market Cagr (2026 2036)")
| Country | CAGR |
|---|---|
| USA | 7.7% |
| UK | 7.3% |
| EU | 7.4% |
| Japan | 7.6% |
| South Korea | 7.5% |
- The USA leads at 7.7% CAGR, driven by guideline adoption, clinical education on EPI recognition, and insurance coverage expansion.
- Japan at 7.6% reflects advanced diagnostic practices, aging population pancreatic disease prevalence, and established laboratory infrastructure.
- South Korea at 7.5% shows growth from health system modernization and increasing gastroenterology specialist adoption of non-invasive pancreatic function testing.
The global fecal pancreatic elastase testing market is projected to grow at 7.6% CAGR from 2026 to 2036. The study covers more than 30 countries, and the main markets are listed below.
Demand Outlook for Fecal Pancreatic Elastase Testing Market in the United States
The US market leads at 7.7% CAGR through 2036. AGA guideline endorsement, expanding insurance coverage for pancreatic function testing, and clinical education programs targeting gastroenterologists and endocrinologists sustain demand growth. Growing recognition of EPI in diabetic populations is broadening test utilization.
- AGA guideline endorsement creates standardized clinical demand for FPE-1 testing in pancreatic function evaluation pathways.
- Insurance coverage expansion for pancreatic function testing supports patient access across commercial and government healthcare programs.
- Clinical education on EPI recognition in diabetic populations is broadening test utilization beyond traditional gastroenterology indications.
Future Outlook for Fecal Pancreatic Elastase Testing Market in the United Kingdom
The UK market grows at 7.3% CAGR through 2036. NICE guideline recommendations, NHS laboratory infrastructure, and clinical awareness programs support FPE-1 testing adoption. Cost-effectiveness evidence for non-invasive pancreatic function assessment supports continued NHS funding.
- NICE guideline recommendations create standardized demand for FPE-1 testing across NHS hospital and GP practice settings.
- NHS laboratory infrastructure supports high-throughput FPE-1 ELISA testing with established diagnostic pathways.
- Clinical education programs on EPI recognition are expanding test utilization among NHS primary care physicians.
Opportunity Analysis for Fecal Pancreatic Elastase Testing Market in the EU
The EU market grows at 7.4% CAGR through 2036. German and French gastroenterology practice guidelines, established diagnostic laboratory infrastructure, and EU in vitro diagnostic regulation compliance support market development.
- German gastroenterology guidelines create structured demand for FPE-1 testing in pancreatic disease evaluation.
- EU IVD regulation compliance requirements set quality and performance standards for FPE-1 diagnostic products.
- Established diagnostic laboratory networks in Western Europe support high-volume FPE-1 ELISA testing deployment.
In-depth Analysis of Fecal Pancreatic Elastase Testing Market in Japan
Japan grows at 7.6% CAGR through 2036. Advanced clinical diagnostic practices, aging population pancreatic disease prevalence, and strict quality standards for diagnostic products sustain demand. Japanese hospital laboratories prioritize high-precision quantitative immunoassay platforms for pancreatic function assessment.
- Aging population prevalence of chronic pancreatitis and diabetes creates expanding clinical demand for EPI testing.
- High-precision diagnostic culture favors quantitative ELISA platforms with strong analytical validation data.
- Hospital laboratory infrastructure supports integration of FPE-1 testing into automated multi-analyte diagnostic workflows.
Sales Analysis for Fecal Pancreatic Elastase Testing Market in South Korea
South Korea grows at 7.5% CAGR through 2036. Health system modernization, expanding gastroenterology specialist infrastructure, and growing adoption of non-invasive diagnostic biomarkers sustain demand. Korean health insurance coverage for diagnostic testing supports patient access.
- Health system modernization supports adoption of standardized non-invasive pancreatic function testing protocols.
- Expanding gastroenterology specialist workforce supports clinical adoption and utilization of FPE-1 testing.
- Health insurance coverage for diagnostic testing enables broad patient access to pancreatic function assessment.
Competitive Landscape and Strategic Positioning
- ScheBo Biotech AG leads as the originator of the pancreatic elastase-1 stool test with the most extensive clinical validation dataset and global laboratory distribution.
- Immundiagnostik AG and BUHLMANN Laboratories AG maintain strong positions in FPE-1 immunoassay platforms for European and global laboratory markets.
- BioServUK Ltd. and DRG Instruments GmbH compete on FPE-1 ELISA kit manufacturing for laboratory and point-of-care testing applications.
The competitive landscape is concentrated among specialized diagnostic manufacturers with validated FPE-1 assay platforms. ScheBo Biotech AG leads as the original developer of the pancreatic elastase stool test with the largest body of clinical validation evidence. Immundiagnostik AG and BUHLMANN Laboratories offer competitive FPE-1 ELISA platforms with established laboratory distribution.
BioServUK and DRG Instruments serve the European laboratory market. Alpha Laboratories distributes FPE-1 testing products in the UK. Bio-Techne offers FPE-1 assays as part of its broader immunoassay portfolio. Competition centers on assay analytical sensitivity, clinical validation depth, laboratory automation compatibility, and regulatory market access.
Entry barriers include clinical validation requirements, regulatory approval timelines, established clinical reference data, and the specialized nature of the pancreatic elastase-1 immunoassay technology. The limited number of validated FPE-1 assay manufacturers creates a concentrated competitive landscape.
Key Companies in the Fecal Pancreatic Elastase Testing Market
Key global companies leading the fecal pancreatic elastase testing market include:
- ScheBo Biotech AG (Germany), Immundiagnostik AG (Germany), and BUHLMANN Laboratories AG (Switzerland) lead with validated FPE-1 assay platforms, extensive clinical evidence, and global laboratory distribution.
- BioServUK Ltd. (UK) and DRG Instruments GmbH (Germany) hold strong positions in European FPE-1 ELISA kit manufacturing and distribution.
- Alpha Laboratories Ltd. (UK), Bio-Techne Corporation (USA), and Medipan GmbH (Germany) are gaining traction in FPE-1 testing through distribution partnerships and immunoassay platform integration.
Competitive Benchmarking: Fecal Pancreatic Elastase Testing Market
| Company | Clinical Validation | Lab Automation | Distribution | Product Range |
|---|---|---|---|---|
| ScheBo Biotech AG | High | Medium | Global | Focused |
| Immundiagnostik AG | High | Medium | Europe, Global | Medium |
| BUHLMANN Laboratories | High | Medium | Global | Broad |
| BioServUK Ltd. | Medium | Low | UK, Europe | Focused |
| DRG Instruments GmbH | Medium | Medium | Europe | Medium |
| Alpha Laboratories | Medium | Low | UK | Focused |
| Bio-Techne Corporation | Medium | Medium | North America | Broad |
| Medipan GmbH | Medium | Low | Europe | Focused |
Source: Future Market Insights competitive analysis, 2026.
Key Developments in Fecal Pancreatic Elastase Testing Market
- In 2025, ScheBo Biotech AG introduced an updated pancreatic elastase-1 ELISA with improved sample preparation protocol reducing laboratory processing time for high-throughput applications.
- In 2025, BUHLMANN Laboratories AG expanded FPE-1 testing availability on its automated immunoassay platform for integration with hospital laboratory diagnostic workflows.
Key Players in the Fecal Pancreatic Elastase Testing Market
Major Global Players
- ScheBo Biotech AG
- Immundiagnostik AG
- BUHLMANN Laboratories AG
- BioServUK Ltd.
- DRG Instruments GmbH
Emerging Players/Startups
- Microba Life Sciences
- Enzymit
- DayTwo
Report Scope and Coverage
| Parameter | Details |
|---|---|
| Market size by 2036 | USD 39.2 billion |
| Growth rate | 7.6% CAGR (2026 to 2036) |
| Forecast period | 2026 to 2036 |
| Base year value (2025) | USD 17.5 billion |
| Key Segment Covered | Product, Sample, Application, Technology, End Use, Distribution Channel |
| Regions covered | North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries covered | USA, South Korea, UK, Japan, Germany, 30 plus countries |
| Key companies profiled | ScheBo Biotech AG, Immundiagnostik AG, BUHLMANN Laboratories AG, BioServUK Ltd., DRG Instruments GmbH, Alpha Laboratories, Bio-Techne Corporation, Medipan GmbH |
| Approach | Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions. |
Market Segmentation Analysis
Fecal Pancreatic Elastase Testing Market Segmented by Product:
- Fecal Pancreatic Elastase ELISA Kits
- Manual ELISA Kits
- 96 Well Kits
- High Throughput Kits
- Automated ELISA Kits
- Integrated Systems
- Laboratory Systems
- Manual ELISA Kits
- Rapid Fecal Pancreatic Elastase Kits
- Lateral Flow Kits
- Cassette Tests
- Strip Tests
- Point of Care Kits
- Reader Based Kits
- Reader Free Kits
- Lateral Flow Kits
- Chemiluminescence Kits
- High Sensitivity Kits
- Central Laboratory Systems
- Automated Platforms
- High Sensitivity Kits
- Fluorescence Immunoassay Kits
- Portable Systems
- Portable Analyzers
- Desktop Analyzers
- Multiplex Panels
- Digestive Panels
- Pancreatic Panels
- Portable Systems
Fecal Pancreatic Elastase Testing Market Segmented by Sample:
- Stool Samples
- Fresh Samples
- Routine Testing
- Monitoring Tests
- Preserved Samples
- Buffered Samples
- Transport Samples
- Fresh Samples
- Frozen Samples
- Research Samples
- Biobank Samples
- Clinical Samples
- Reference Samples
- Stored Samples
- Specialty Samples
- Research Samples
- Other Samples
- Duodenal Samples
- Advanced Testing
- Research Testing
- Experimental Samples
- Biomarker Studies
- Translational Studies
- Duodenal Samples
Fecal Pancreatic Elastase Testing Market Segmented by Application:
- Exocrine Pancreatic Insufficiency
- Chronic Pancreatitis
- Severity Monitoring
- Function Monitoring
- Cystic Fibrosis
- Pediatric Monitoring
- Digestive Assessment
- Chronic Pancreatitis
- Diabetes Associated Dysfunction
- Type 1 Diabetes
- Early Detection
- Long Term Monitoring
- Type 2 Diabetes
- Metabolic Assessment
- Complication Screening
- Type 1 Diabetes
- Gastrointestinal Disorders
- Malabsorption Disorders
- Absorption Assessment
- Digestive Evaluation
- Chronic Diarrhea
- Differential Diagnosis
- Screening Tests
- Malabsorption Disorders
- Pancreatic Cancer Assessment
- Post Surgical Monitoring
- Recovery Monitoring
- Enzyme Evaluation
- Oncology Diagnostics
- Cancer Screening
- Treatment Monitoring
- Post Surgical Monitoring
Fecal Pancreatic Elastase Testing Market Segmented by Technology:
- Enzyme Linked Immunosorbent Assay
- Manual Platforms
- Routine Testing
- Batch Processing
- Automated Platforms
- High Volume Systems
- Integrated Systems
- Manual Platforms
- Rapid Immunochromatographic Assays
- Lateral Flow Technology
- Visual Detection
- Digital Detection
- Quantitative Assays
- Portable Systems
- Clinic Systems
- Lateral Flow Technology
- Chemiluminescence Immunoassay
- High Sensitivity Systems
- Central Laboratory Systems
- Reference Systems
- Integrated Platforms
- Automated Systems
- Precision Platforms
- High Sensitivity Systems
- Fluorescence Immunoassay
- Fluorescence Systems
- Portable Systems
- Desktop Systems
- Multiplex Systems
- Digestive Panels
- Advanced Panels
- Fluorescence Systems
Fecal Pancreatic Elastase Testing Market Segmented by End Use:
- Hospitals
- Public Hospitals
- Government Hospitals
- University Hospitals
- Private Hospitals
- Multi Specialty Hospitals
- Corporate Hospitals
- Public Hospitals
- Diagnostic Laboratories
- Independent Laboratories
- Reference Laboratories
- Regional Laboratories
- Hospital Laboratories
- Integrated Networks
- Advanced Laboratories
- Independent Laboratories
- Specialty Clinics
- Gastroenterology Clinics
- Digestive Centers
- Pancreatic Clinics
- Endocrinology Clinics
- Diabetes Centers
- Metabolic Clinics
- Gastroenterology Clinics
- Academic and Research Institutes
- Clinical Institutes
- Pancreatic Research
- Digestive Research
- Academic Laboratories
- University Programs
- Translational Programs
- Clinical Institutes
Fecal Pancreatic Elastase Testing Market Segmented by Distribution Channel:
- Direct Sales
- Manufacturer Sales
- Hospital Contracts
- Laboratory Contracts
- Inside Sales
- Institutional Sales
- Key Accounts
- Manufacturer Sales
- Distributor Sales
- Medical Distributors
- National Networks
- Regional Partners
- Diagnostic Suppliers
- Laboratory Suppliers
- Specialty Suppliers
- Medical Distributors
- Online Sales
- E Procurement
- Hospital Portals
- Laboratory Portals
- Third Party Platforms
- Medical Platforms
- Diagnostic Platforms
- E Procurement
Fecal Pancreatic Elastase Testing Market by Region:
- North America
- USA
- Canada
- Mexico
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Western Europe
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- East Asia
- China
- Japan
- South Korea
- South Asia and Pacific
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Türkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
Research Sources and Bibliography
- 1. American Gastroenterological Association. (2025). AGA Clinical Practice Guideline: Diagnosis and Management of Exocrine Pancreatic Insufficiency. AGA.
- 2. European Pancreatic Club. (2025). EPC Guidelines on Pancreatic Function Testing. EPC.
- 3. World Health Organization. (2025). WHO Global Report on Pancreatic Disease Burden and Management. WHO.
- 4. National Institute for Health and Care Excellence. (2025). NICE Diagnostics Guidance: Pancreatic Elastase Testing for EPI. NICE.
- 5. ScheBo Biotech AG. (2025). Pancreatic Elastase-1 Stool Test: Clinical Validation and Performance Report. ScheBo.
This bibliography is provided for reader reference.
This Report Answers
- Estimating the size of the market and how much revenue it is projected to generate from 2026 to 2036.
- Segmentation by product, sample, application, technology, end use, distribution channel.
- Insights about more than 30 markets in the region.
- Analysis of product types including ELISA kits, rapid tests, and automated immunoassay platforms.
- Assessment of the competitive landscape.
- Finding investment opportunities in EPI diagnosis, treatment monitoring, diabetes screening, and point-of-care testing.
- Keeping track of the supply chain.
- Delivery of data in PDF and Excel formats.
Frequently Asked Questions
How big is the fecal pancreatic elastase testing market in 2026?
The global fecal pancreatic elastase testing market is estimated to be valued at USD 18.8 billion in 2026.
What will be the size of the fecal pancreatic elastase testing market in 2036?
The market size for the fecal pancreatic elastase testing market is projected to reach USD 39.2 billion by 2036.
How much will the fecal pancreatic elastase testing market growth be between 2026 and 2036?
The fecal pancreatic elastase testing market is expected to grow at a 7.6% CAGR between 2026 and 2036.
What are the key products in the fecal pancreatic elastase testing market?
The key products in the fecal pancreatic elastase testing market are Fecal Pancreatic Elastase ELISA Kits, Rapid Fecal Pancreatic Elastase Kits, Chemiluminescence Kits and Fluorescence Immunoassay Kits.
Which sample segment is expected to contribute a significant share in the fecal pancreatic elastase testing market in 2026?
In terms of sample, the stool samples segment is expected to command 88.0% share in the fecal pancreatic elastase testing market in 2026.
Preview the report firsthand - request a free sample
Get SampleGet the brochure for pricing and purchase details.
Get PDFTable of Content
- Key Takeaways
- Market Size and CAGR
- Top Growth Driver
- Fastest Growing Segment
- Leading Region
- Key Companies
- Emerging Opportunities
- Executive Summary
- Global Market Outlook
- Demand-side Trends
- Supply-side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Analyst Perspective (What is happening? Why now? What should investors know?)
- Key Questions Answered
- How large is the market?
- What is the CAGR?
- What are key trends?
- Which region dominates?
- Who are the leaders?
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Expert Input and Fieldwork (Primary Evidence)
- Tooling, Models, and Reference Databases
- Data Engineering and Model Build
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics (Drivers, Restraints, Opportunity, Trends)
- Scenario Forecast (Optimistic, Likely, Conservative)
- Impact Analysis
- AI Impact
- Sustainability Impact
- Regulatory Impact
- Technology Impact
- Consumer / Buyer Analysis
- Purchase Drivers
- Adoption Barriers
- Buyer Journey
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter's Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Global Market Analysis and Forecast, 2021 to 2036
- Historical Market Size Value (USD Million) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
- Y-o-Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis, 2021 to 2036
- Global Market Analysis and Forecast, By Product, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Product, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Product, 2026 to 2036
- Fecal Pancreatic Elastase ELISA Kits
- Manual ELISA Kits
- Automated ELISA Kits
- Rapid Fecal Pancreatic Elastase Kits
- Lateral Flow Kits
- Point of Care Kits
- Chemiluminescence Kits
- High Sensitivity Kits
- Fluorescence Immunoassay Kits
- Portable Systems
- Multiplex Panels
- Fecal Pancreatic Elastase ELISA Kits
- Y-o-Y Growth Trend Analysis By Product, 2021 to 2025
- Absolute $ Opportunity Analysis By Product, 2026 to 2036
- Global Market Analysis and Forecast, By Sample, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Sample, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Sample, 2026 to 2036
- Stool Samples
- Fresh Samples
- Preserved Samples
- Frozen Samples
- Research Samples
- Reference Samples
- Other Samples
- Duodenal Samples
- Experimental Samples
- Stool Samples
- Y-o-Y Growth Trend Analysis By Sample, 2021 to 2025
- Absolute $ Opportunity Analysis By Sample, 2026 to 2036
- Global Market Analysis and Forecast, By Application, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Application, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Application, 2026 to 2036
- Exocrine Pancreatic Insufficiency
- Chronic Pancreatitis
- Cystic Fibrosis
- Diabetes Associated Dysfunction
- Type 1 Diabetes
- Type 2 Diabetes
- Gastrointestinal Disorders
- Malabsorption Disorders
- Chronic Diarrhea
- Pancreatic Cancer Assessment
- Post Surgical Monitoring
- Oncology Diagnostics
- Exocrine Pancreatic Insufficiency
- Y-o-Y Growth Trend Analysis By Application, 2021 to 2025
- Absolute $ Opportunity Analysis By Application, 2026 to 2036
- Global Market Analysis and Forecast, By Technology, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Technology, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Technology, 2026 to 2036
- Enzyme Linked Immunosorbent Assay
- Manual Platforms
- Automated Platforms
- Rapid Immunochromatographic Assays
- Lateral Flow Technology
- Quantitative Assays
- Chemiluminescence Immunoassay
- High Sensitivity Systems
- Integrated Platforms
- Fluorescence Immunoassay
- Fluorescence Systems
- Multiplex Systems
- Enzyme Linked Immunosorbent Assay
- Y-o-Y Growth Trend Analysis By Technology, 2021 to 2025
- Absolute $ Opportunity Analysis By Technology, 2026 to 2036
- Global Market Analysis and Forecast, By End Use, 2021 to 2036
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By End Use, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By End Use, 2026 to 2036
- Hospitals
- Public Hospitals
- Private Hospitals
- Diagnostic Laboratories
- Independent Laboratories
- Hospital Laboratories
- Specialty Clinics
- Gastroenterology Clinics
- Endocrinology Clinics
- Academic and Research Institutes
- Clinical Institutes
- Academic Laboratories
- Hospitals
- Y-o-Y Growth Trend Analysis By End Use, 2021 to 2025
- Absolute $ Opportunity Analysis By End Use, 2026 to 2036
- Global Market Analysis and Forecast, By Distribution Channel
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Distribution Channel, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Distribution Channel, 2026 to 2036
- Direct Sales
- Manufacturer Sales
- Inside Sales
- Distributor Sales
- Medical Distributors
- Diagnostic Suppliers
- Online Sales
- E Procurement
- Third Party Platforms
- Direct Sales
- Y-o-Y Growth Trend Analysis By Distribution Channel, 2021 to 2025
- Absolute $ Opportunity Analysis By Distribution Channel, 2026 to 2036
- Global Market Analysis and Forecast, By Region, 2021 to 2036
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis and Forecast, By Country, 2021 to 2036
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- USA
- Canada
- Mexico
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Key Takeaways
- Latin America Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Key Takeaways
- Western Europe Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Key Takeaways
- Eastern Europe Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Key Takeaways
- East Asia Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- China
- Japan
- South Korea
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Key Takeaways
- South Asia and Pacific Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Key Takeaways
- Middle East & Africa Market Analysis and Forecast, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Türkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Key Takeaways
- Key Countries Market Analysis
- USA
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Canada
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Mexico
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Brazil
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Chile
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- UK
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Italy
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- France
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- India
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Russia
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Poland
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Hungary
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Türkiye
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- South Africa
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- USA
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Product
- By Sample
- By Application
- By Technology
- By End Use
- By Distribution Channel
- Emerging Startups
- Innovation Benchmarking
- Competition Analysis
- Competition Deep Dive
- ScheBo Biotech AG
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Region/Sales Channel)
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- BioServUK Ltd.
- Immundiagnostik AG
- DRG Instruments GmbH
- Alpha Laboratories Ltd.
- BIOSERV Diagnostics GmbH
- BÜHLMANN Laboratories AG
- Fitzgerald Industries International
- Medipan GmbH
- Bio-Techne Corporation
- ScheBo Biotech AG
- Case Studies
- Success Stories
- Recent Developments
- Competition Deep Dive
- Assumptions & Acronyms Used
